Neuraminidase inhibitors--the story behind the Cochrane review
- 7 December 2009
- Vol. 339 (dec07 2) , b5164
- https://doi.org/10.1136/bmj.b5164
Abstract
Although billions have been spent on oseltamivir in the face of pandemic influenza, the team updating the Cochrane review of neuraminidase inhibitors in healthy adults found that the public evidence base for this global public health drug was fragmented and inconsistent. Peter Doshi tells the storyKeywords
This publication has 7 references indexed in Scilit:
- Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysisBMJ, 2009
- Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2009
- Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with OseltamivirDrug Safety, 2008
- Does This Patient Have Influenza?JAMA, 2005
- Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and HospitalizationsArchives of internal medicine (1960), 2003
- Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trialThe Lancet, 2000
- Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute InfluenzaJAMA, 2000